Comparing Sublingual and Inhaled Cannabis Therapies for Low Back Pain: An Observational Open-Label Study

Rambam Maimonides Medical Journal- October 2022  Volume 13  Issue 4
2022
Dror Robinson, M.D., Ph.D, Sivan Ritter, D.V.M., B.A.,2 and Mustafa Yassin

ABSTRACT
Background and Objective: Medical cannabis is becoming an acceptable treatment modality in
medicine, especially for pain relief. Concurrently, cannabis use is becoming more prevalent worldwide, a
public demand-driven trend despite the lack of established scientific basis. This observational open-label
study sought to investigate the effectiveness of cannabis therapy for alleviating low back pain symptoms.
Methods: Two types of cannabis treatment modalities were sequentially administered to chronic low back
pain patients. After an initial 1-month washout period (WO1), the first modality was cannabidiol (CBD)-rich
sublingual extract treatment administered for 10 months. Following another washout period, the second
modality, Δ⁹-tetrahydrocannabinol (THC)-rich smoked inflorescence (whole dried cannabis flowers) was
administered for 12 months.

This library aims to empower you with knowledge but it does not replace the personalized advice and guidance a healthcare professional can provide. Before implementing any changes to your health regimen based on the contents of this library, we strongly advise you to consult with a qualified healthcare professional. Your doctor’s expertise is essential for interpreting how these insights may apply to your unique health circumstances.